Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Pulmonary Hypertension
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA) pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF), measured using a previously implanted hemodynamic…
- Trial name
- ARNIMEMS-HFpEF (NCT04753112)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital
Heart Failure With Preserved Ejection Fraction, Iron Deficiencies
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Iron Deficiencies, Acute Heart Failure
- Trial name
- COREVIVE-HFpEF (NCT05991128)
- Testing
- Ferric derisomaltose
- Where
- China
- Volunteers
- 170 people
- Sponsor
- China-Japan Friendship Hospital
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure
Effects of a Multidisciplinary Integrated Care Model on Care Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases and is associated with frequent hospitalizations, poor quality of life, and limited effective treatment options.
- Trial name
- MICM-HFpEF (NCT07798856)
- Testing
- Multidisciplinary Integrated Care Model (MICM), Usual Care
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chimei Medical Center
Heart Failure With Preserved Ejection Fraction
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Heart Failure (HF) in Australia affects 1-2% of the population. Heart failure with preserved ejection fraction (HFpEF) refers to a syndrome of clinical heart failure without impairment of systolic cardiac function.
- Trial name
- NCT05129722
- Testing
- Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- The George Institute
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Type2diabetes, Heart Failure With Preserved Ejection Fraction
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome.
- Trial name
- NCT06337812
- Testing
- Potato Starch
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan
Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)
- Trial name
- NCT07093528
- Testing
- Cardiovascular Magnetic Resonance (CMR)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Heart Failure With Preserved Ejection Fraction, Malnutrition
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
HF is an advanced or terminal stage of various heart diseases, with high rehospitalization and mortality rates. In HF patients, undernutrition is not uncommon and represents one of the most significant determinants of poor…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Malnutrition, Aged, Prognosis
- Trial name
- NCT05586828
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Beijing Tongren Hospital
Chronic Obstructive Pulmonary Disease, Heart Failure
HFpEF and 2-year Mortality of COPD Patients
This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease
- Trial name
- THERESE (NCT04277429)
- Testing
- Cardiac function assessment
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Olomouc
Heart Failure With Preserved Ejection Fraction
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials.
- Trial name
- NCT05562063
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Juan Badimon
Heart Failure With Preserved Ejection Fraction
The Efficacy and Safety of Zhigancao Tang Granule for HFpEF of Qi-Yin Dificiency
This study was designed as a randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the efficacy and safety of Zhigancao Tang granule in patients with HFpEF of Qi-Yin dificiency.
- Trial name
- HFpEF (NCT04317339)
- Testing
- Zhigancao Tang granule
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Heart Failure With Preserved Ejection Fraction (HFpEF)
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Heart failure with preserved ejection fraction (HFpEF), a certain type of heart failure, occurs when the heart doesn't pump blood around the body properly. It can cause breathlessness, tiredness, and swollen feet or ankles.
- Trial name
- TRAITS-HFpEF (NCT05383287)
- Where
- United Kingdom
- Volunteers
- 1,250 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure With Normal Ejection Fraction
Cell Therapy in HFpEF
The primary objective of the study is to investigate safety and efficacy of transendocardial CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and function, patient exercise capacity and…
- Trial name
- CELLpEF (NCT02923609)
- Testing
- Cell Therapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-TIRZSEMA (NCT06914141)
- Testing
- Tirzepatide, Semaglutide
- Where
- United States
- Volunteers
- 28,118 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- SP9In-HFpEF (NCT05312021)
- Testing
- IMR-687
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
HFpEF - Heart Failure With Preserved Ejection Fraction, Colchicine
Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates.
- Trial name
- NCT05637398
- Testing
- Colchicine
- Where
- 2 sites in Russia
- Volunteers
- 42 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation